In a phase 2 RCT, BI 690517 caused an initial eGFR decrease and reduced albuminuria, with or without background SGLT2 inhibitor use, when added on top of RAS blockade in participants with CKD [eGFR 30–<90 ml/min/1.73 m2, urine albumin:creatinine ratio (UACR) ≥200 mg/g] [42]. The gene discussed is SLC5A2; the disease is chronic kidney disease.